EMA keeps a lid on how drugs and vaccines reach Europe, funding safety, efficacy and post-market checks.
New lawsuits claim GLP-1 diabetes drugs may cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition. Regulators are reviewing evidence, while manufacturers dispute the claims. Reports cite studies showing mixed results on risk, with the absolute risk remaining very low.